2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.07 Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC)

P1.06B.07 Association of NEDD9 Expression and Survival of Patients with KRAS Mutant and STK11 Mutant Non-Small Cell Lung Cancer (KRASMUT/STK11MUT-NSCLC)

Back to course

Pdf Summary

This study investigates the association between NEDD9 expression and survival in patients with KRAS and STK11 mutant non-small cell lung cancer (KS-NSCLC). Using a cohort of 1852 KS-NSCLC specimens with detailed genetic sequencing, tumors were categorized into high and low NEDD9 expression groups based on RNA levels. High NEDD9 expression was linked to improved overall survival (OS) for patients, regardless of their TP53 mutation status. <br /><br />Notably, patients with high NEDD9 and wild-type TP53 had better median OS compared to those with mutant TP53. Conversely, low NEDD9 expression showed similar OS outcomes irrespective of TP53 status, indicating that NEDD9 could be a more potent prognosticator than TP53 in these cancers.<br /><br />The study highlights that high NEDD9 expression predicts better survival independent of co-occurring mutations in KEAP1 and SMARCA4, which are typically associated with poor outcomes. Furthermore, PD-L1 positivity, known for its role in immune checkpoint therapies, was inversely related to NEDD9 expression, yet this relationship did not confound the impact of NEDD9 on survival.<br /><br />The findings suggest that NEDD9 could serve as a valuable biomarker for prognosis in KS-NSCLC and possibly guide treatment strategies, such as incorporating chemotherapy with dual immunotherapy in front-line settings when actionable genomic alterations are absent. Given NEDD9's role as an intracellular scaffolding protein, future research is warranted to explore its signaling mechanisms, which might unveil new therapeutic avenues despite its challenging target profile.<br /><br />The study underscores the potential of integrating NEDD9 expression into commercial molecular panels to refine prognostic assessments and therapeutic decisions in non-small cell lung cancer.

Asset Subtitle

Julia Judd

Meta Tag

Speaker Julia Judd

Topic Pathology & Biomarkers

Keywords

NEDD9 expression

survival

KRAS

STK11

non-small cell lung cancer

TP53 mutation

biomarker

prognosis

PD-L1

immunotherapy